☆ 4.1 Article

Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2024)

Related references

Note: Only part of the references are listed.

Review Energy & Fuels

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma

Thomas U. Marron et al.

Summary: The treatment paradigm for hepatocellular carcinoma has recently improved with new combinations of targeted and immunotherapies. Studies have shown that perioperative immunotherapy can significantly improve outcomes for patients with resectable HCC.

FUEL (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma

Assaf Magen et al.

Summary: The response to anti-PD-1 in hepatocellular carcinoma patients is associated with the expansion of CXCL13(+)CD4(+) helper T cells and effector-like CD8(+) T cells, as well as the presence of dendritic cells enriched in maturation and regulatory molecules. Tumors rich in T cells often fail to respond to immune checkpoint blockade, but the clonal expansion of specific T cell subsets correlates with response to treatment. The interaction between Progenitor CD8(+) T cells, CXCL13(+) T-H cells, and mregDC plays a role in controlling the differentiation of tumor-specific exhausted CD8(+) T cells following immune checkpoint blockade.

NATURE MEDICINE (2023)

Add to Collection

News Item Dermatology

Neoadjuvant pembrolizumab improves eventfree survival in melanoma

T. Schwarz

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Add to Collection

Review Oncology

Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art

Alena Laschtowitz et al.

Summary: Hepatocellular carcinoma (HCC) necessitates a multidisciplinary evaluation for personalized treatment. Liver resection and transplantation are the main curative treatment options, but disease recurrence remains a burden. Immune checkpoint inhibitors (ICI) have shown promising results in palliative care. However, neoadjuvant ICI therapy is not recommended due to lack of evidence from large Phase III trials. The risk of allograft rejection is a major concern in the context of liver transplantation.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2023)

Add to Collection

Article Medicine, General & Internal

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Sapna P. Patel et al.

Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Gastroenterology & Hepatology

Declining disease burden of HCC in the United States, 1992-2017: A population-based analysis

Jianglong Han et al.

Summary: According to data analysis, the incidence and mortality of HCC have decreased in the United States in recent years, especially since 2013. This may be attributed to changing etiologies, advances in screening and diagnosis, and improved treatment modality and allocation.

HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Ahmed Omar Kaseb et al.

Summary: This study aimed to evaluate the safety and tolerability of perioperative immunotherapy in patients with resectable hepatocellular carcinoma. The findings suggest that nivolumab alone or in combination with ipilimumab is safe and feasible in this patient population, supporting further studies of immunotherapy in the perioperative setting for hepatocellular carcinoma.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Thomas U. Marron et al.

Summary: This study evaluated the clinical activity of neoadjuvant cemiplimab in patients with resectable hepatocellular carcinoma. The results showed that treatment with cemiplimab resulted in significant tumor necrosis and partial response in some patients. Adverse events were common but severe adverse events were rare. These findings contribute to further understanding the clinical benefit of preoperative PD-1 blockade in patients with hepatocellular carcinoma.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Review Oncology

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma

Thomas U. Marron et al.

Summary: The treatment paradigm for hepatocellular carcinoma has improved with the introduction of new combinations of targeted and immunotherapies. However, the majority of patients who undergo surgical resection develop recurrent HCC and there is currently no perioperative therapy that significantly improves survival. Recent studies suggest that neoadjuvant immunotherapy may be a promising approach for patients with resectable HCC.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2022)

Add to Collection

Review Gastroenterology & Hepatology

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Josep M. Llovet et al.

HEPATOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Current epidemiology in hepatocellular carcinoma

Peter Konyn et al.

Summary: This review discusses the risk factors, global trends, and high incidence rates of HCC in Asia and Africa. Interventions to minimize the global burden of HCC include reducing common risk factors, treating underlying causes effectively, and implementing comprehensive screening programs for HCC. Healthcare inequity is identified as a crucial area for improvement in addressing disparities in HCC incidence and mortality among racial and ethnic minorities in multiethnic countries.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Oncology

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

Won Jin Ho et al.

Summary: A study evaluating neoadjuvant cabozantinib and nivolumab in patients with hepatocellular carcinoma (HCC) showed that 80% of patients successfully underwent hepatic resection surgery, with 42% having major pathological responses. An in-depth biospecimen profiling indicated an orchestrated contribution of B cells to antitumor immunity in HCC, with effector T cells, tertiary lymphoid structures, CD138(+) plasma cells, and a distinct spatial arrangement of B cells being enriched in responders compared to nonresponders.

NATURE CANCER (2021)

Add to Collection

Review Multidisciplinary Sciences

Neoadjuvant checkpoint blockade for cancer immunotherapy

Suzanne L. Topalian et al.

SCIENCE (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

Alexander C. Huang et al.

NATURE MEDICINE (2019)

Add to Collection

Review Gastroenterology & Hepatology

Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma

Clifford Akateh et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

Add to Collection

Article Medicine, General & Internal

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

G. K. Abou-Alfa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

P. M. Forde et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Immunology

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Christopher S. Garris et al.

IMMUNITY (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Christian U. Blank et al.

NATURE MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix et al.

LANCET (2017)

Add to Collection

Article Gastroenterology & Hepatology

Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship With Clinical and Pathological Features

Julien Calderaro et al.

HEPATOLOGY (2016)

Add to Collection

Article Oncology

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

Jing Liu et al.

CANCER DISCOVERY (2016)

Add to Collection

Article Surgery

Recurrence of Hepatocellular Cancer After Resection Patterns, Treatments, and Prognosis

Parissa Tabrizian et al.

ANNALS OF SURGERY (2015)

Add to Collection

Article Surgery

Anatomical versus non-anatomical resection for hepatocellular carcinoma

S. Marubashi et al.

BRITISH JOURNAL OF SURGERY (2015)

Add to Collection

Article Multidisciplinary Sciences

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Naiyer A. Rizvi et al.

SCIENCE (2015)

Add to Collection

Review Immunology

Liver fibrosis and repair: immune regulation of wound healing in a solid organ

Antonella Pellicoro et al.

NATURE REVIEWS IMMUNOLOGY (2014)

Add to Collection

Review Medicine, General & Internal

Molecular origins of cancer - Cancer immunology

Olivera J. Finn

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Hematology

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy

Fumihiko Tsushima et al.

BLOOD (2007)

Add to Collection

Article Surgery

Early and late recurrence after liver resection for hepatocellular carcinoma - Prognostic and therapeutic implications

N Portolani et al.

ANNALS OF SURGERY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.